Drug intelligence / Profile preview

PF-07911145

Development stage: Unknown
Lead developer: Pfizer
Modality: Prophylactic Vaccines → Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
Administration: Intramuscular

Overview

**PF-07911145** (also known as BNT167) is an investigational **mRNA-based prophylactic vaccine** developed by Pfizer in collaboration with BioNTech for the prevention of **varicella** (chickenpox) and potentially **herpes zoster** (shingles), caused by the varicella-zoster virus. It encodes viral antigens to induce immune responses, including neutralizing antibodies and T-cell immunity, against the herpesvirus. The vaccine advanced to **Phase 1** clinical trials but has since been **dropped** from further development.[5][7][9][13][15]

Targets

gE (VZV glycoprotein E)VZV glycoproteins (Varicella-zoster virus glycoproteins)

Beyond the preview

Go deeper on PF-07911145.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PF-07911145.

Explore the full profile